CN114615996A - 通过溶瘤腺病毒、cdk4/6抑制剂和其他治疗活性剂的组合治疗肿瘤 - Google Patents

通过溶瘤腺病毒、cdk4/6抑制剂和其他治疗活性剂的组合治疗肿瘤 Download PDF

Info

Publication number
CN114615996A
CN114615996A CN202080070210.1A CN202080070210A CN114615996A CN 114615996 A CN114615996 A CN 114615996A CN 202080070210 A CN202080070210 A CN 202080070210A CN 114615996 A CN114615996 A CN 114615996A
Authority
CN
China
Prior art keywords
inhibitor
adenovirus
cells
combination
cdk4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080070210.1A
Other languages
English (en)
Chinese (zh)
Inventor
佩尔·松内·霍尔姆
罗曼·纳夫罗特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Teaching Center Technical University Of Munich
Original Assignee
Clinical Teaching Center Technical University Of Munich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinical Teaching Center Technical University Of Munich filed Critical Clinical Teaching Center Technical University Of Munich
Publication of CN114615996A publication Critical patent/CN114615996A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080070210.1A 2019-09-05 2020-09-07 通过溶瘤腺病毒、cdk4/6抑制剂和其他治疗活性剂的组合治疗肿瘤 Pending CN114615996A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19000396.2 2019-09-05
EP19000396 2019-09-05
EP19000406.9 2019-09-12
EP19000406 2019-09-12
PCT/EP2020/074980 WO2021044061A1 (en) 2019-09-05 2020-09-07 Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent

Publications (1)

Publication Number Publication Date
CN114615996A true CN114615996A (zh) 2022-06-10

Family

ID=72428285

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080070210.1A Pending CN114615996A (zh) 2019-09-05 2020-09-07 通过溶瘤腺病毒、cdk4/6抑制剂和其他治疗活性剂的组合治疗肿瘤

Country Status (8)

Country Link
US (1) US20220354911A1 (cg-RX-API-DMAC7.html)
EP (1) EP4025229A1 (cg-RX-API-DMAC7.html)
JP (1) JP7834342B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220079551A (cg-RX-API-DMAC7.html)
CN (1) CN114615996A (cg-RX-API-DMAC7.html)
AU (1) AU2020342594A1 (cg-RX-API-DMAC7.html)
CA (1) CA3152965A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021044061A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4578943A4 (en) * 2022-08-25 2026-02-25 Fujifilm Corp PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1655827A (zh) * 2002-05-27 2005-08-17 佩尔·松内·霍尔姆 腺病毒和编码其的核酸的新应用
US20170202893A1 (en) * 2014-09-24 2017-07-20 Salk Institute For Biological Studies Oncolytic tumor viruses and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2012022496A2 (en) * 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
SG11201507393TA (en) * 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
RU2670762C2 (ru) * 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途
WO2018195202A1 (en) * 2017-04-21 2018-10-25 Pellficure Pharmaceuticals Inc. Compositions and methods for the treatment of cancer
CA3066778A1 (en) * 2017-06-21 2018-12-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
SG11202007873VA (en) * 2018-03-05 2020-09-29 Klinikum Rechts Der Isar Der Technischen Univ Muenchen Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1655827A (zh) * 2002-05-27 2005-08-17 佩尔·松内·霍尔姆 腺病毒和编码其的核酸的新应用
US20170202893A1 (en) * 2014-09-24 2017-07-20 Salk Institute For Biological Studies Oncolytic tumor viruses and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASHISH P. SHAH等: "A Review on DNA Repair Inhibition by PARP inhibitors in cancer Therapy", 《FOLIA MEDICA》 *
MONTSERRAT PEREZ-SALVIA等: "Bromodomain inhibitors and cancer therapy: From structures to applications", 《EPIGENETCS》 *
NADIIA LYPOVA等: "Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy", 《CANCERS》 *
YUJUN ZHAO 等, SMALL-MOLECULE INHIBITORS OF THE MDM2-P53 PROTEIN-PROTEIN INTERACTION (MDM2 INHIBITORS) IN CLINICAL TRIALS FOR CANCER TREATMENT *

Also Published As

Publication number Publication date
JP2022547885A (ja) 2022-11-16
AU2020342594A1 (en) 2022-03-10
CA3152965A1 (en) 2021-03-11
JP7834342B2 (ja) 2026-03-24
WO2021044061A1 (en) 2021-03-11
US20220354911A1 (en) 2022-11-10
KR20220079551A (ko) 2022-06-13
EP4025229A1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
JP2025013934A (ja) 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置
EA028590B1 (ru) Ингибиторы мет для повышения эффективности лучевой терапии
Vaughan et al. p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity
Zhang et al. EGF receptor signaling modulates YAP activation and promotes experimental proliferative vitreoretinopathy
Zeng et al. Adenovirus early region 3 RIDα protein limits NFκB signaling through stress-activated EGF receptors
US20220280590A1 (en) Use of inhibitors of yap and sox2 for the treatment of cancer
Holzmüller et al. YB‐1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma
US11911450B2 (en) Method for managing pain
Cheng et al. Reduced expression of PDZK1 mediates fibroblast activation and cardiac fibrosis via EGFR phosphorylation in diabetic cardiomyopathy
JP7834342B2 (ja) 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置
Song et al. Cardiomyocyte‐specific overexpression of FPN1 diminishes cardiac hypertrophy induced by chronic intermittent hypoxia
Xing et al. A dual-peptides and specific promoter-modified nano gene delivery system for myocardial hypertrophy treatment
RU2835886C1 (ru) Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента
RU2811278C2 (ru) Лечение опухолей комбинацией онколитического аденовируса и ингибитора cdk4/6
US20130157959A1 (en) Use of hades as tumor suppressor target
Guo et al. Antiglioma effects of combined use of a baculovirual vector expressing wild‐type p53 and sodium butyrate
Zang et al. Chromatin remodeling factor CHRAC1 regulates doxorubicin-induced cardiotoxicity via IRF9/GSDMD/CASP-1
US20100311809A1 (en) Viral vector system, a composition comprising the viral vector system and its use
CN102056631A (zh) 细胞凋亡诱导物
Cai et al. Overexpression of GJB1–13k induces mitochondrial calcium overload and triggers apoptosis and GSDME-mediated pyroptosis in cervical cancer
Dong et al. Intravitreal delivery of LATS1 mRNA by lipid nanoparticles as an effective strategy for uveal melanoma therapy
Yang et al. YBX1 Modulated Corneal Neovascularization Induced by Alkali Burn via m5C-Dependent Regulation of the STAT3/HIF-1α/VEGFA Axis
Kankanamge et al. Nrf1 coordinates proteasome activity and autophagy to maintain cardiac proteostasis
WO2025097153A1 (en) Fam222a as a therapeutic target
JP2024542196A (ja) 黄斑変性症を処置するための材料及び方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220610